- Home
- CSQ vs FOLD Comparison
CSQ vs FOLD Comparison
Compare CSQ & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSQ
- FOLD
- Stock Information
- Founded
- CSQ 2003
- FOLD 2002
- Country
- CSQ United States
- FOLD United States
- Employees
- CSQ N/A
- FOLD N/A
- Industry
- CSQ Finance Companies
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- CSQ Finance
- FOLD Health Care
- Exchange
- CSQ Nasdaq
- FOLD Nasdaq
- Market Cap
- CSQ 2.8B
- FOLD 2.8B
- IPO Year
- CSQ N/A
- FOLD 2007
- Fundamental
- Price
- CSQ $18.01
- FOLD $9.66
- Analyst Decision
- CSQ
- FOLD Strong Buy
- Analyst Count
- CSQ 0
- FOLD 8
- Target Price
- CSQ N/A
- FOLD $17.57
- AVG Volume (30 Days)
- CSQ 220.3K
- FOLD 2.5M
- Earning Date
- CSQ 01-01-0001
- FOLD 11-06-2024
- Dividend Yield
- CSQ 7.53%
- FOLD N/A
- EPS Growth
- CSQ N/A
- FOLD N/A
- EPS
- CSQ N/A
- FOLD N/A
- Revenue
- CSQ N/A
- FOLD $493,671,000.00
- Revenue This Year
- CSQ N/A
- FOLD $33.97
- Revenue Next Year
- CSQ N/A
- FOLD $21.74
- P/E Ratio
- CSQ N/A
- FOLD N/A
- Revenue Growth
- CSQ N/A
- FOLD 32.58
- 52 Week Low
- CSQ $12.50
- FOLD $9.02
- 52 Week High
- CSQ $16.45
- FOLD $14.57
- Technical
- Relative Strength Index (RSI)
- CSQ 59.69
- FOLD 32.67
- Support Level
- CSQ $17.55
- FOLD $9.37
- Resistance Level
- CSQ $18.18
- FOLD $9.68
- Average True Range (ATR)
- CSQ 0.21
- FOLD 0.49
- MACD
- CSQ -0.01
- FOLD -0.15
- Stochastic Oscillator
- CSQ 74.23
- FOLD 8.84
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's investment strategy is to provide total return through a combination of capital appreciation and current income. Its investment portfolio consists of equities, convertible securities and high-yield corporate bonds.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.